Faisal, Muhammad Kim, Jae Ho Yoo, Kyung Ho Roh, Eun Joo Hong, Soon Sun Lee, So Ha 2024-01-19T15:33:07Z 2024-01-19T15:33:07Z 2021-09-02 2021-01-14 0022-2623 https://pubs.kist.re.kr/handle/201004/117528 NUAK isoforms, NUAK1 (ARK5) and NUAK2 (SNARK), are important members of the AMPK family of protein kinases. They are involved in a broad spectrum of physiological and cellular events, and sometimes their biological roles overlap. NUAK isoform dysregulation is associated with numerous pathological disorders, including neurodegeneration, metastatic cancer, and diabetes. Therefore, they are promising therapeutic targets in metabolic diseases and cancers; consequently, various NUAK-targeted inhibitors have been disclosed. The first part of this review comprises a brief discussion of the homology, expression, structure, and characteristics of NUAK isoforms. The second part focuses on NUAK isoforms' involvement in crucial biological operations, including mechanistic findings, highlighting how their abnormal functioning contributes to disease progression and quality of life. The third part summarizes the key findings and applications of targeting NUAK isoforms for treating multiple cancers and neurodegenerative disorders. The final part systematically presents a critical review and analysis of the literature on NUAK isoform inhibitions through small molecules. English AMER CHEMICAL SOC VENTRAL BODY-WALL EPITHELIAL-MESENCHYMAL TRANSITION LIGHT-CHAIN PHOSPHORYLATION AMPK-MEDIATED REGULATION KINASE INHIBITOR PROTEIN-KINASE GLUCOSE-TRANSPORT TARGETING NUAK1 SUPPRESSES INVASION MYOSIN PHOSPHATASE Development and Therapeutic Potential of NUAKs Inhibitors Article 10.1021/acs.jmedchem.0c00533 1 JOURNAL OF MEDICINAL CHEMISTRY, v.64, no.1, pp.2 - 25 JOURNAL OF MEDICINAL CHEMISTRY 64 1 2 25 scie scopus 000611409600002 2-s2.0-85099134744 Chemistry, Medicinal Pharmacology & Pharmacy Article VENTRAL BODY-WALL EPITHELIAL-MESENCHYMAL TRANSITION LIGHT-CHAIN PHOSPHORYLATION AMPK-MEDIATED REGULATION KINASE INHIBITOR PROTEIN-KINASE GLUCOSE-TRANSPORT TARGETING NUAK1 SUPPRESSES INVASION MYOSIN PHOSPHATASE NUAK1 NUAK2 ARK5 SNARK Cancer Inhibitors